SCHEDULE: Icahn Affiliates Consent to Enzon Pharma Merger, Charter Amend
Shareholder Consent for Corporate Action
Icahn Enterprises affiliates have provided written consent to the merger and certificate of incorporation amendment for Enzon Pharmaceuticals, Inc.
Summary
- Carl C. Icahn and his affiliates, Icahn Enterprises Holdings L.P. and Icahn Enterprises G.P. Inc., beneficially own 36,056,636 shares of Enzon Pharmaceuticals, Inc. common stock, representing 48.6% of the class.
- On January 30, 2026, affiliates of Icahn Enterprises Holdings delivered written consent to Enzon Pharmaceuticals, Inc.
- This consent approves the previously disclosed Merger and an amendment to the Issuer's certificate of incorporation.
- The consent was provided pursuant to the IEH Support Agreement between Icahn Enterprises Holdings, certain affiliates, Enzon Pharmaceuticals, Inc., and Viskase.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, procedural update confirming a major shareholder's approval for a corporate transaction, which is neither inherently positive nor negative without further context on the merger terms.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that this filing reflects a significant step in a corporate transaction, likely a take-private or strategic acquisition, given the substantial ownership stake of Icahn Enterprises and their consent to a merger. Such actions are common in industries undergoing consolidation or where activist investors seek to unlock value through structural changes.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Certificate of Incorporation Amendment | Affiliates of Icahn Enterprises Holdings delivered written consent approving an amendment to the Issuer's certificate of incorporation. | NA | This amendment will alter the foundational governing document of Enzon Pharmaceuticals, Inc., potentially affecting shareholder rights, corporate structure, or operational flexibility, subject to the specific details of the amendment. |
Related Party Transactions
- The IEH Support Agreement involves Icahn Enterprises Holdings and certain of its affiliates with the Issuer and Viskase, indicating a pre-existing arrangement between related parties concerning the securities and corporate actions.
Stakeholder Impact
- Shareholders: The approval of the Merger and certificate amendment by a significant shareholder (Icahn, 48.6%) indicates a high likelihood of these corporate actions proceeding, which will directly impact all shareholders through the terms of the merger and changes to corporate governance.
Next Steps
- Completion of the Merger.
- Implementation of the amendment to the Issuer's certificate of incorporation.
Key Dates
| Date | Description |
|---|---|
| 2008-03-14 | Original Schedule 13D filing date. |
| 2026-01-30 | Date of event requiring this filing: Icahn affiliates delivered written consent for the Merger and certificate of incorporation amendment. |
Keywords
Enzon Pharmaceuticals, Icahn Enterprises, Carl Icahn, Schedule 13D, Merger Consent, Corporate Governance, Certificate of Incorporation, Shareholder Consent, IEH Support Agreement, Viskase
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.